SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Abstract

The authors carried out a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes.

Citation
Zelniker TA, Wiviott SD, Raz I, et al. Lancet. 2019;393:31–9.